Nervotec to help NFL Alumni with digital health screenings

Nervotec, a digital health R&D company based in Singapore today will team up with the National Football League Alumni Association (NFLA), in an exclusive partnership after a year-long comprehensive global shortlist of selected technology providers involving tests and trials. With various advanced technologies such as remote photoplethysmography (rPPG) and AI recognised for its data accuracy, Nervotec will co-develop sports performance insights for athletes with NFLA from remote vital signs data analytics at NFL Alumni Performance Labs. As the only technology provider to make the cut among global competitors, the partnership highlights the Singapore HealthTech company's first deal with a major sports performance brand in the United States and an advancement for remote patient monitoring technologies.




Dr Chuck Morris, CEO of NFL Alumni Performance Labs, said, "The inclusion of predictive vital sign analytics will be key in delivering our state-of-the-art sports performance facilities all over the US. We are glad to continue our development of these technologies with Nervotec to help our athletes reach greater heights."


On top of contributing to performance sports science, Nervotec's real-world technology application advances research towards managing chronic disease. According to the Centers for Disease Control and Prevention (CDC), telehealth interventions such as remote patient monitoring technologies and mobile health (mHealth) that are supported by predictive vital sign analytics have been proven to be effective in mitigating chronic disease risk factors. With predictive vital sign analytics, chronic disease risk can be quantified and actionable steps such as tailored workout routines can be proposed according to the individuals' chronic disease risk profiles.


Nervotec's computer vision algorithm technology known as remote photoplethysmography (rPPG) uses a mobile phone's camera that records the patient's face which allows for healthcare practitioners to remotely and efficiently measure vital signs. Further applications are being developed with AI that calculates risk of influenza-like illnesses, cardiovascular disease and other comorbidities. This is currently undergoing clinical validation in Singapore in which results will be used for the Health Science Authority's medical certification.


Dr Ian Mathews, Medical & AI advisor to Nervotec and Deputy Group CTO of the National University Hospital of Singapore said, "The partnership with NFL Alumni Performance Labs validates Nervotec's technological application beyond the borders of Singapore that has the potential for far-reaching global impact. The application of predictive vital sign analytics is also a significant step in advancing the development of telehealth intervention, an emerging healthcare technology."